Mallinckrodt Pharmaceuticals' OFIRMEV injection has received a Prior Approval Supplement from the U.S. Food and Drug Administration.
OFIREMEV will now be available in an intravenous bag, giving an additional method of delivery to health care providers.
The Prior Approval Supplement will include the new container closure and the manufacturer of the product being added. Fresenius Kabi will take on the job of manufacturing the polypropylene bags.
Mallinckrodt expects the product to hit the market in the second quarter of 2017.